The companies struck a multi-year strategic collaboration, under which GSK will have access to Helix's GenoSphere cohorts.
Axovia Therapeutics Nabs $1.1M Grant to Advance BBS1 Vision Loss Gene Therapy Toward Clinical Trials
With this new grant, nonprofit A Race Against Blindness has provided a total of $5.1 million to advance AXV-101.
The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.
The collaboration will support development of Ascidian's RNA exon editor therapy, ACDN-01, for treating the rare genetic eye disease.
The deal brings Dark Blue's preclinical oncology products, including an MLLT1/3-targeted agent for leukemias, into Amgen's portfolio.
The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.
Researchers will test whether the company's Genomic Prostate Score assay predicts disease progression and outcomes in a prospective cohort.
Cartography will be eligible to receive more than $850 million, if Pfizer exercises all options and brings a drug from the collaboration to the market.
The firm plans to enroll US patients into the trial of GEB-101 in the second quarter, having launched an investigator-initiated trial in China.
Under the old guidelines, women were assessed for ovarian cancer if their CA125 levels in blood tests reached or exceeded 35 IU/ml, regardless of age. But CA125 is not an accurate predictor of ovarian ...
The firm will retrospectively analyze data from more than 1,100 breast cancer patients treated in Unicancer's clinical trials.
Stories about federal funding cuts, lab test regulation, and increasing adoption of DPYD testing were the most popular among readers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback